mirtazapine has been researched along with Alzheimer Disease in 11 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Replication of the potential effects of mirtazapine in the subgroup of those with depression in dementia with "psychological" symptoms would be valuable." | 9.30 | Sertraline and Mirtazapine Versus Placebo in Subgroups of Depression in Dementia: Findings From the HTA-SADD Randomized Controlled Trial. ( Banerjee, S; Chua, KC; Hellier, J; Voshaar, RO; Zuidersma, M, 2019) |
| "A 79-year old female patient with Alzheimer's disease developed acute dystonia twelve hours after taking a single dose of mirtazapine 30 mg." | 7.73 | [Mirtazapine-induced dystonia in a patient with Alzheimer's disease]. ( Bouckaert, F; Peuskens, J; van den Bosch, S, 2006) |
| "Three patients with dementia and depression complicated by weight loss, insomnia, and anxiety were treated with mirtazapine at an outpatient memory loss clinic of a university hospital." | 7.71 | Mirtazapine for treatment of depression and comorbidities in Alzheimer disease. ( Brady, SR; Raji, MA, 2001) |
| " Replication of the potential effects of mirtazapine in the subgroup of those with depression in dementia with "psychological" symptoms would be valuable." | 5.30 | Sertraline and Mirtazapine Versus Placebo in Subgroups of Depression in Dementia: Findings From the HTA-SADD Randomized Controlled Trial. ( Banerjee, S; Chua, KC; Hellier, J; Voshaar, RO; Zuidersma, M, 2019) |
| "Overall, in the short-term treatment, these data suggest that commonly used antidepressants sertraline and mirtazapine should be considered as an alternative treatment for depression in AD patients." | 5.12 | Efficacy of antidepressant drugs in the treatment of depression in Alzheimer disease patients: A systematic review and network meta-analysis. ( Bai, Y; He, Y; Huang, J; Huang, S; Huang, W; Li, H; Li, Y, 2021) |
| "A 79-year old female patient with Alzheimer's disease developed acute dystonia twelve hours after taking a single dose of mirtazapine 30 mg." | 3.73 | [Mirtazapine-induced dystonia in a patient with Alzheimer's disease]. ( Bouckaert, F; Peuskens, J; van den Bosch, S, 2006) |
| "Three patients with dementia and depression complicated by weight loss, insomnia, and anxiety were treated with mirtazapine at an outpatient memory loss clinic of a university hospital." | 3.71 | Mirtazapine for treatment of depression and comorbidities in Alzheimer disease. ( Brady, SR; Raji, MA, 2001) |
| "Treatment with mirtazapine or placebo had no effect on cognitive and functional status as assessed by the Mini-Mental State Examination and the Katz scale, respectively." | 2.84 | Mirtazapine does not improve sleep disorders in Alzheimer's disease: results from a double-blind, placebo-controlled pilot study. ( Camargos, EF; Louzada, LL; Naves, JO; Nóbrega, OT; Quintas, JL; Scoralick, FM, 2017) |
| "The prevalence of insomnia increases with age and affects up to 35% of community-dwelling adults with dementia." | 2.45 | Non-pharmacologic treatment of insomnia in persons with dementia. ( Darvishi, R; Kunik, ME; Shub, D, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| He, Y | 1 |
| Li, H | 1 |
| Huang, J | 1 |
| Huang, S | 1 |
| Bai, Y | 1 |
| Li, Y | 1 |
| Huang, W | 1 |
| Zuidersma, M | 1 |
| Chua, KC | 1 |
| Hellier, J | 2 |
| Voshaar, RO | 1 |
| Banerjee, S | 2 |
| Scoralick, FM | 1 |
| Louzada, LL | 1 |
| Quintas, JL | 1 |
| Naves, JO | 1 |
| Camargos, EF | 1 |
| Nóbrega, OT | 1 |
| Kálmán, J | 2 |
| Shub, D | 1 |
| Darvishi, R | 1 |
| Kunik, ME | 1 |
| Brodaty, H | 1 |
| Dewey, M | 1 |
| Romeo, R | 1 |
| Ballard, C | 1 |
| Baldwin, R | 1 |
| Bentham, P | 1 |
| Fox, C | 1 |
| Holmes, C | 1 |
| Katona, C | 1 |
| Knapp, M | 1 |
| Lawton, C | 1 |
| Lindesay, J | 1 |
| Livingston, G | 1 |
| McCrae, N | 1 |
| Moniz-Cook, E | 1 |
| Murray, J | 1 |
| Nurock, S | 1 |
| Orrell, M | 1 |
| O'Brien, J | 1 |
| Poppe, M | 1 |
| Thomas, A | 1 |
| Walwyn, R | 1 |
| Wilson, K | 1 |
| Burns, A | 1 |
| Ahmed, A | 1 |
| Palotás, A | 1 |
| Puskás, LG | 1 |
| Kitajka, K | 1 |
| Palotás, M | 1 |
| Molnár, J | 1 |
| Pákáski, M | 1 |
| Janka, Z | 1 |
| Penke, B | 1 |
| van den Bosch, S | 1 |
| Bouckaert, F | 1 |
| Peuskens, J | 1 |
| Raji, MA | 1 |
| Brady, SR | 1 |
4 reviews available for mirtazapine and Alzheimer Disease
| Article | Year |
|---|---|
Efficacy of antidepressant drugs in the treatment of depression in Alzheimer disease patients: A systematic review and network meta-analysis.
Topics: Alzheimer Disease; Antidepressive Agents; Cognition; Depression; Humans; Mirtazapine; Network Meta-A | 2021 |
[Genomical and metabolomical abnormalities in Alzheimer disease and in experimental models].
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Antidepressive Agents; Apolipoprotein E4 | 2008 |
Non-pharmacologic treatment of insomnia in persons with dementia.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Antidepressive Agents, Tricyclic; Circadian Rhyth | 2009 |
Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Dementia; Depressive Disorder; Do | 2011 |
3 trials available for mirtazapine and Alzheimer Disease
| Article | Year |
|---|---|
Sertraline and Mirtazapine Versus Placebo in Subgroups of Depression in Dementia: Findings From the HTA-SADD Randomized Controlled Trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Dementia; Depression; Double-Blin | 2019 |
Mirtazapine does not improve sleep disorders in Alzheimer's disease: results from a double-blind, placebo-controlled pilot study.
Topics: Actigraphy; Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Tricyclic; Brazil; Do | 2017 |
Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Dementia; Depressive Disorder; Do | 2011 |
5 other studies available for mirtazapine and Alzheimer Disease
| Article | Year |
|---|---|
Antidepressant treatment in Alzheimer's disease.
Topics: Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Dementia; Depressive Disorder; Double-B | 2011 |
Neutropenia associated with mirtazapine use: is a drop in the neutrophil count in a symptomatic older adults a cause for concern?
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Tricyclic; Depression; Female; Hu | 2002 |
Altered response to mirtazapine on gene expression profile of lymphocytes from Alzheimer's patients.
Topics: Aged; Alzheimer Disease; Antidepressive Agents, Tricyclic; Female; Gene Expression Profiling; Humans | 2004 |
[Mirtazapine-induced dystonia in a patient with Alzheimer's disease].
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Alzheimer Disease; Dystonia; Female; Humans; Mian | 2006 |
Mirtazapine for treatment of depression and comorbidities in Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Tricyclic; Comorbidity; Depressio | 2001 |